tetano
Editor, Senior Moderator
Sci Transl Med
. 2022 Jul 21;eabn4338.
doi: 10.1126/scitranslmed.abn4338. Online ahead of print.
Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated individuals
Stijn P Andeweg[SUP] #[/SUP][SUP] 1 [/SUP], Harry Vennema[SUP] #[/SUP][SUP] 1 [/SUP], Irene Veldhuijzen[SUP] 1 [/SUP], Naomi Smorenburg[SUP] 1 [/SUP], Dennis Schmitz[SUP] 1 [/SUP], Florian Zwagemaker[SUP] 1 [/SUP], Arianne B van Gageldonk-Lafeber[SUP] 1 [/SUP], Susan J M Hahné[SUP] 1 [/SUP], Chantal Reusken[SUP] 1 [/SUP], Mirjam J Knol[SUP] #[/SUP][SUP] 1 [/SUP], Dirk Eggink[SUP] #[/SUP][SUP] 1 [/SUP], SeqNeth Molecular surveillance group†; RIVM COVID-19 Molecular epidemiology group†
Affiliations
Abstract
The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) break through infection- or vaccine-induced immunity is not well understood. We analyzed 28,578 sequenced SARS-CoV-2 samples from individuals with known immune status obtained through national community testing in the Netherlands from March to August 2021. We found evidence of an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta (B.1.617.2) variants compared to the Alpha (B.1.1.7) variant after vaccination. No clear differences were found between vaccines. However, the effect was larger in the first 14-59 days after complete vaccination compared to ≥60 days. In contrast to vaccine-induced immunity, there was no increased risk for re-infection with Beta, Gamma or Delta variants relative to Alpha variant in individuals with infection-induced immunity.
. 2022 Jul 21;eabn4338.
doi: 10.1126/scitranslmed.abn4338. Online ahead of print.
Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated individuals
Stijn P Andeweg[SUP] #[/SUP][SUP] 1 [/SUP], Harry Vennema[SUP] #[/SUP][SUP] 1 [/SUP], Irene Veldhuijzen[SUP] 1 [/SUP], Naomi Smorenburg[SUP] 1 [/SUP], Dennis Schmitz[SUP] 1 [/SUP], Florian Zwagemaker[SUP] 1 [/SUP], Arianne B van Gageldonk-Lafeber[SUP] 1 [/SUP], Susan J M Hahné[SUP] 1 [/SUP], Chantal Reusken[SUP] 1 [/SUP], Mirjam J Knol[SUP] #[/SUP][SUP] 1 [/SUP], Dirk Eggink[SUP] #[/SUP][SUP] 1 [/SUP], SeqNeth Molecular surveillance group†; RIVM COVID-19 Molecular epidemiology group†
Affiliations
- PMID: 35862508
- DOI: 10.1126/scitranslmed.abn4338
Abstract
The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) break through infection- or vaccine-induced immunity is not well understood. We analyzed 28,578 sequenced SARS-CoV-2 samples from individuals with known immune status obtained through national community testing in the Netherlands from March to August 2021. We found evidence of an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta (B.1.617.2) variants compared to the Alpha (B.1.1.7) variant after vaccination. No clear differences were found between vaccines. However, the effect was larger in the first 14-59 days after complete vaccination compared to ≥60 days. In contrast to vaccine-induced immunity, there was no increased risk for re-infection with Beta, Gamma or Delta variants relative to Alpha variant in individuals with infection-induced immunity.